Initiation of oral anticoagulation after acute ischaemic stroke or transient ischaemic attack: Timing and complications of overlapping heparin or conventional treatment

Cerebrovascular Diseases

Volumn 26, Issue 2, 2008, Pages 171-177

  Audebert, Heinrich J ^a   Schenk, Berit ^b   Tietz, Viola ^b   Schenkel, Johannes ^b   Heuschmann, Peter U ^c  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b Munich Municipal Hospital   (Germany)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Antithrombotic treatment; Aspirin; Atrial fibrillation; Bridging; Heparin; Oral anticoagulation; Phenprocoumon; Stroke, acute treatment

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CERTOPARIN; DALTEPARIN; ENOXAPARIN; HEPARIN; NADROPARIN; PHENPROCOUMON; REVIPARIN; TINZAPARIN;

ACUTE DISEASE; AGED; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; BRAIN INFARCTION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMMUNITY HOSPITAL; CONJUNCTIVAL HEMORRHAGE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; EMBOLISM; EXTRACRANIAL HEMORRHAGE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART INFARCTION; HEMATURIA; HEMORRHAGIC STROKE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; ISCHEMIA; LOW DRUG DOSE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROLOGIC DISEASE; OBSERVATIONAL STUDY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RECURRENT DISEASE; STROKE; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VASCULAR DEATH; VASCULAR DISEASE;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; DRUG ADMINISTRATION SCHEDULE; FEMALE; FIBRINOLYTIC AGENTS; GERMANY; HEPARIN; HUMANS; ISCHEMIC ATTACK, TRANSIENT; LENGTH OF STAY; MALE; PHENPROCOUMON; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; STROKE; TREATMENT OUTCOME;

EID: 49949115986     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000145324     Document Type: Article

References (28)

1. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 1993;342:1255-1262.
2. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-1457.
3. Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, Gorelick P, Halperin J, Harbaugh R, Johnston SC, Katzan I, Kelly-Hayes M, Kenton EJ, Marks M, Schwamm LH, Tomsick T: Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Circulation 2006;113:e409-e449.
4. D'Angelo A, Della VP, Crippa L, Fattorini A, Pattarini E, Vigano DS: Relationship between international normalized ratio values, vitamin K-dependent clotting factor levels and in vivo prothrombin activation during the early and steady phases of oral anticoagulant treatment. Haematologica 2002;87:1074-1080.
5. Saxena R, Lewis S, Berge E, Sandercock PA, Koudstaal PJ: Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischemic stroke and atrial fibrillation in the International Stroke Trial. Stroke 2001;32:2333-2337.
6. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. JAMA 1998;279:1265-1272.
7. Berge E, Abdelnoor M, Nakstad PH, Sandset PM: Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. Lancet 2000;355:1205-1210.
8. Berge E, Sandercock P: Anticoagulants versus antiplatelet agents for acute ischaemic stroke. Cochrane Database Syst Rev 2002;4:CD003242.
9. Hart RG, Palacio S, Pearce LA: Atrial fibrillation, stroke, and acute antithrombotic therapy: analysis of randomized clinical trials. Stroke 2002;33:2722-2727.
10. O'Donnell MJ, Berge E, Sandset PM: Are there patients with acute ischemic stroke and atrial fibrillation that benefit from low molecular weight heparin? Stroke 2006;37:452-455.
11. Al Sadat A, Sunbulli M, Chaturvedi S: Use of intravenous heparin by North American neurologists: do the data matter? Stroke 2002;33:1574-1577.
12. Kudesia R, Chaturvedi S: Practice variation among Michigan neurologists in the use of intravenous heparin. J Neurol Sci 2002;202:25-27.
13. Schmidt WP, Heuschmann P, Taeger D, Henningsen H, Buecker-Nott HJ, Berger K: Determinants of IV heparin treatment in patients with ischemic stroke. Neurology 2004;63:2407-2409.
14. Kim MH, Decena BF, Bruckman D, Eagle KA: Use patterns of low-molecular weight heparin and the impact on length of stay in patients hospitalized for atrial fibrillation. Am Heart J 2003;145:665-669.
15. Dunn A, Bioh D, Beran M, Capasso M, Siu A: Effect of intravenous heparin administration on duration of hospitalization. Mayo Clin Proc 2004;79:159-163.
16. Audebert HJ, Wimmer ML, Hahn R, Schenkel J, Bogdahn U, Horn M, Haberl RL: Can telemedicine contribute to fulfill WHO Helsingborg Declaration of specialized stroke care? Cerebrovasc Dis 2005;20:362-369.
17. Audebert HJ, Schenkel J, Heuschmann PU, Bogdahn U, Haberl RL: Effects of the implementation of a telemedical stroke network: the Telemedic Pilot Project for Integrative Stroke Care (TEMPiS) in Bavaria, Germany. Lancet Neurol 2006;5:742-748.
18. Audebert HJ, Wimmer ML, Schenkel J, Ulm K, Kolominsky-Rabas PL, Bogdahn U, Horn M, Haberl RL: Telemedicine stroke department network. Introduction of a telemedicine pilot project for integrated stroke management in South Bavaria and analysis of its efficiency (in German). Nervenarzt 2004;75:161-165.
19. Heuschmann PU, Biegler MK, Busse O, Elsner S, Grau A, Hasenbein U, Hermanek P, Janzen RW, Kolominisky-Rabas PL, Kraywinkel K, Lowitzsch K, Misselwitz B, Nabavi DG, Otten K, Pientka L, von Reutern GM, Ringelstein EB, Sander D, Wagner M, Berger K: Development and implementation of evidence-based indicators for measuring quality of acute stroke care: the Quality Indicator Board of the German Stroke Registers Study Group (ADSR). Stroke 2006;37:2573-2578.
20. Vahedi K, Amarenco P: Cardiac Causes of Stroke. Curr Treat Options Neurol 2000;2:305-318.
21. Heuschmann PU, Kolominsky-Rabas PL, Misselwitz B, Hermanek P, Leffmann C, Janzen RW, Rother J, Buecker-Nott HJ, Berger K: Predictors of in-hospital mortality and attributable risks of death after ischemic stroke: the German Stroke Registers Study Group. Arch Intern Med 2004;164:1761-1768.
22. European Stroke Initiative recommendations for stroke management. European Stroke Council, European Neurological Society and European Federation of Neurological Societies. Cerebrovasc Dis 2000;10:335-351.
23. Hacke W, Kaste M, Olsen TS, Orgogozo JM, Bogousslavsky J: Recommendations of the European Stroke Initiative for the management and treatment of stroke (in German). Nervenarzt 2001;72:807-819.
24. Audebert HJ (ed): Standardisierte Optimierte Prozeduren in der akuten Schlaganfallversorgung. Adaptiert für das TEMPiS-Modell; www.tempis.de
25. Chamorro A, Vila N, Ascaso C, Blanc R: Heparin in acute stroke with atrial fibrillation: clinical relevance of very early treatment. Arch Neurol 1999;56:1098-1102.
26. Spyropoulos AC: Bridging of oral anticoagulation therapy for invasive procedures. Curr Hematol Rep 2005;4:405-413.
27. Dunn AS, Spyropoulos AC, Turpie AG: Bridging therapy in patients on long-term oral anticoagulants who require surgery: the Prospective Peri-operative Enoxaparin Cohort Trial (PROSPECT). J Thromb Haemost 2007;5:2211-2218.
28. Chamorro A: Immediate anticoagulation for acute stroke in atrial fibrillation: yes. Stroke 2006;37:3052-3053.